2014 Q4 Form 10-Q Financial Statement
#000119312514394063 Filed on November 03, 2014
Income Statement
Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
---|---|---|---|
Revenue | $220.5K | $201.0K | $253.4K |
YoY Change | -49.28% | -20.67% | -4.12% |
Cost Of Revenue | $90.00K | $73.71K | $113.4K |
YoY Change | 12.5% | -34.99% | -30.89% |
Gross Profit | $130.0K | $127.3K | $140.0K |
YoY Change | -63.89% | -9.07% | 39.73% |
Gross Profit Margin | 58.96% | 63.33% | 55.25% |
Selling, General & Admin | $810.0K | $565.1K | $2.558M |
YoY Change | -65.68% | -77.91% | 60.23% |
% of Gross Profit | 623.08% | 443.93% | 1827.42% |
Research & Development | $550.0K | $597.0K | $6.907M |
YoY Change | -48.6% | -91.36% | 1050.81% |
% of Gross Profit | 423.08% | 469.0% | 4934.1% |
Depreciation & Amortization | $10.00K | $10.00K | $20.00K |
YoY Change | -50.0% | -50.0% | 0.0% |
% of Gross Profit | 7.69% | 7.86% | 14.29% |
Operating Expenses | $1.360M | $1.162M | $9.465M |
YoY Change | -60.33% | -87.72% | 330.88% |
Operating Profit | -$1.230M | -$1.035M | -$9.325M |
YoY Change | -59.91% | -88.9% | 344.8% |
Interest Expense | $10.00K | $1.305K | $1.546K |
YoY Change | -200.0% | -15.59% | -99.66% |
% of Operating Profit | |||
Other Income/Expense, Net | $0.00 | $5.305K | $41.00 |
YoY Change | 12839.02% | -100.01% | |
Pretax Income | -$1.220M | -$1.030M | -$9.325M |
YoY Change | -60.39% | -88.96% | 264.85% |
Income Tax | $0.00 | $0.00 | |
% Of Pretax Income | |||
Net Earnings | -$1.224M | -$1.030M | -$9.325M |
YoY Change | -60.27% | -88.96% | 264.85% |
Net Earnings / Revenue | -554.9% | -512.19% | -3680.5% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$337.0K | -$284.5K | -$3.393M |
COMMON SHARES | |||
Basic Shares Outstanding | 36.18M shares | 36.18M shares | 27.51M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $10.45M | $11.76M | $8.270M |
YoY Change | -35.81% | 42.2% | -29.68% |
Cash & Equivalents | $10.45M | $11.76M | $8.268M |
Short-Term Investments | |||
Other Short-Term Assets | $120.0K | $220.0K | $230.0K |
YoY Change | -33.33% | -4.35% | -39.47% |
Inventory | $439.2K | $263.9K | $223.3K |
Prepaid Expenses | |||
Receivables | $15.61K | $26.31K | $58.88K |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $11.02M | $12.28M | $8.777M |
YoY Change | -34.4% | 39.87% | -29.73% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $109.3K | $26.30K | $38.20K |
YoY Change | 306.09% | -31.16% | -57.56% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $109.3K | $26.30K | $38.20K |
YoY Change | 306.09% | -31.16% | -57.56% |
TOTAL ASSETS | |||
Total Short-Term Assets | $11.02M | $12.28M | $8.777M |
Total Long-Term Assets | $109.3K | $26.30K | $38.20K |
Total Assets | $11.13M | $12.30M | $8.815M |
YoY Change | -33.86% | 39.56% | -29.93% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $710.0K | $600.0K | $2.360M |
YoY Change | -21.98% | -74.58% | 68.57% |
Accrued Expenses | |||
YoY Change | |||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $60.00K | $110.0K | $2.060M |
YoY Change | 0.0% | -94.66% | 2188.89% |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $796.3K | $739.5K | $4.453M |
YoY Change | -19.8% | -83.39% | 154.45% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $796.3K | $739.5K | $4.453M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $800.0K | $740.0K | $4.450M |
YoY Change | -19.19% | -83.37% | 154.29% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$75.94M | -$74.72M | -$67.08M |
YoY Change | 8.25% | 11.4% | |
Common Stock | $86.28M | $86.28M | $30.17K |
YoY Change | 0.33% | 285904.11% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $10.34M | $11.56M | $4.362M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $11.13M | $12.30M | $8.815M |
YoY Change | -33.86% | 39.56% | -29.93% |
Cashflow Statement
Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$1.224M | -$1.030M | -$9.325M |
YoY Change | -60.27% | -88.96% | 264.85% |
Depreciation, Depletion And Amortization | $10.00K | $10.00K | $20.00K |
YoY Change | -50.0% | -50.0% | 0.0% |
Cash From Operating Activities | -$1.180M | -$1.100M | -$1.970M |
YoY Change | -2.48% | -44.16% | 66.95% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$90.00K | $0.00 | -$10.00K |
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $0.00 | |
YoY Change | |||
Cash From Investing Activities | -$90.00K | $0.00 | -$10.00K |
YoY Change | -100.0% | ||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -50.00K | -30.00K | 3.870M |
YoY Change | -100.54% | -100.78% | -67.23% |
NET CHANGE | |||
Cash From Operating Activities | -1.180M | -1.100M | -1.970M |
Cash From Investing Activities | -90.00K | 0.000 | -10.00K |
Cash From Financing Activities | -50.00K | -30.00K | 3.870M |
Net Change In Cash | -1.320M | -1.130M | 1.890M |
YoY Change | -116.46% | -159.79% | -82.22% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$1.180M | -$1.100M | -$1.970M |
Capital Expenditures | -$90.00K | $0.00 | -$10.00K |
Free Cash Flow | -$1.090M | -$1.100M | -$1.960M |
YoY Change | -9.92% | -43.88% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2014Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2014Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
36178944 | shares |
CY2013Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8267888 | |
CY2014Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36178944 | shares |
CY2014Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36178944 | shares |
CY2014Q3 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
||
CY2014Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2014Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2014Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2532094 | shares |
CY2014Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2014Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
CY2014Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2014Q3 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
41200 | |
CY2014Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2014Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
739507 | |
CY2014Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
36179 | |
CY2014Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-74721063 | |
CY2014Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
86248402 | |
CY2014Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
604351 | |
CY2014Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11563518 | |
CY2014Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
12303025 | |
CY2014Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
25592 | |
CY2014Q3 | us-gaap |
Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
|
109564 | |
CY2014Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11764923 | |
CY2014Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
26296 | |
CY2014Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
221637 | |
CY2014Q3 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
11514923 | |
CY2014Q3 | us-gaap |
Assets
Assets
|
12303025 | |
CY2014Q3 | us-gaap |
Inventory Net
InventoryNet
|
263860 | |
CY2014Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
26309 | |
CY2014Q3 | us-gaap |
Assets Current
AssetsCurrent
|
12276729 | |
CY2014Q3 | ogen |
Class Of Warrant Outstanding Weighted Average Exercise Price
ClassOfWarrantOutstandingWeightedAverageExercisePrice
|
1.93 | |
CY2012Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3235982 | shares |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9925967 | |
CY2012Q4 | ogen |
Class Of Warrant Outstanding Weighted Average Exercise Price
ClassOfWarrantOutstandingWeightedAverageExercisePrice
|
3.53 | |
CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
35993944 | shares |
CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
35993944 | shares |
CY2013Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
||
CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
CY2013Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2013Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2747094 | shares |
CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2013Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
CY2013Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2013Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
31500 | |
CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
992847 | |
CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
35994 | |
CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-70155116 | |
CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
85957757 | |
CY2013Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
909957 | |
CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15838635 | |
CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
16831482 | |
CY2013Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
18839 | |
CY2013Q4 | us-gaap |
Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
|
64051 | |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16276510 | |
CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
26913 | |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
175242 | |
CY2013Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
16026510 | |
CY2013Q4 | us-gaap |
Assets
Assets
|
16831482 | |
CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
288383 | |
CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
64434 | |
CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
16804569 | |
CY2013Q4 | ogen |
Class Of Warrant Outstanding Weighted Average Exercise Price
ClassOfWarrantOutstandingWeightedAverageExercisePrice
|
1.91 | |
CY2014Q2 | ogen |
Class Of Warrant Expired Weighted Average Exercise Price
ClassOfWarrantExpiredWeightedAverageExercisePrice
|
10.00 | |
CY2014Q2 | ogen |
Class Of Warrant Expired
ClassOfWarrantExpired
|
5000 | shares |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.41 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-5545205 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
35000 | shares | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27496676 | shares | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | ||
us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
96788 | ||
us-gaap |
Gross Profit
GrossProfit
|
333459 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-151861 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-140865 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12989419 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13136857 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
147438 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
144503 | ||
us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
157031 | ||
us-gaap |
Revenues
Revenues
|
597449 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
17649 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-12989419 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
15098 | ||
us-gaap |
Interest Paid
InterestPaid
|
3108 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-10917 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-27278 | ||
us-gaap |
Interest Expense
InterestExpense
|
3339 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
13470316 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8289614 | ||
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
5180702 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1658079 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
|||
us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
263990 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
64042 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3904775 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3939800 | ||
us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
1624165 | ||
us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
8824 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-17649 | ||
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-280353 | ||
us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
61763 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1624165 | ||
ogen |
Common Stock Issued During Period Par Value For Warrants Exercise
CommonStockIssuedDuringPeriodParValueForWarrantsExercise
|
106 | ||
ogen |
Technology Access Fee Paid In Common Stock And Convertible Note Payable To Shareholder
TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder
|
6000000 | ||
ogen |
Write Off Of Expired Inventory
WriteOffOfExpiredInventory
|
240005 | ||
us-gaap |
Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
|
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Guaranteed Rights of Return</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has granted guaranteed rights of return to two dental distributors. The Company defers recognition of revenue on these accounts until either the distributor provides notification to the Company that the product has been sold to the end consumer or the guaranteed right of return period expires. Once notification has been received and verified, the Company records revenue in that accounting period. The Company had $25,592 and $18,839 of revenue deferred under guaranteed rights of return arrangements included in deferred revenue in the balance sheets as of September 30, 2014 and December 31, 2013, respectively.</p> </div> | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
ORAGENICS INC | ||
dei |
Trading Symbol
TradingSymbol
|
OGEN | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.81 | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Organization</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Oragenics, Inc. (formerly known as Oragen, Inc.) (the “Company” or “we”) was incorporated in November 1996; however, operating activity did not commence until 1999. The Company is focused on the discovery, development and commercialization of a variety of technologies associated with broad spectrum antibiotics, oral health, and other general health benefits.</p> </div> | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4378396 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
37142 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
100000 | shares | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
67391 | shares | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, income tax valuation allowance, inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts.</p> </div> | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36145043 | shares | |
dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-09-30 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001174940 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Concentrations</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company is dependent on key suppliers to provide probiotics, blending, warehousing and packaging of its EvoraPlus, EvoraKids, EvoraPro, and Teddy’s Pride products. The Company had four key suppliers during the three and nine months ended September 30, 2014 and 2013. The majority of the Company’s cost of sales are from these key suppliers during the three and nine months ended September 30, 2014 and 2013. Accounts payable and accrued expenses for these vendors totaled approximately $90,504 and $146,284 as of September 30, 2014 and December 31, 2013, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of September 30, 2014, the uninsured portion of this balance was $11,514,923. As of December 31, 2013, the uninsured portion of this balance was $16,026,510.</p> </div> | ||
us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
113486 | ||
us-gaap |
Gross Profit
GrossProfit
|
440346 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-112604 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-24523 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4565947 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-203 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
20129 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
20376 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-203 | ||
us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
158999 | ||
us-gaap |
Revenues
Revenues
|
719422 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4586323 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-4565947 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
29175 | ||
us-gaap |
Interest Paid
InterestPaid
|
2997 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-38125 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
6753 | ||
us-gaap |
Interest Expense
InterestExpense
|
2856 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
5026669 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2516826 | ||
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2509843 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-4511587 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
|||
us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
279076 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
20119 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-113486 | ||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
424 | ||
us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
188330 | ||
us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
5740 | ||
us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
102500 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-19705 | ||
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-305606 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
290830 | ||
ogen |
Common Stock Issued During Period Par Value For Warrants Exercise
CommonStockIssuedDuringPeriodParValueForWarrantsExercise
|
135 | ||
ogen |
Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
|
0 | shares | |
ogen |
Number Of Dental Distributor With Guaranteed Rights Of Returns
NumberOfDentalDistributorWithGuaranteedRightsOfReturns
|
2 | Customer | |
ogen |
Class Of Warrant Expired Weighted Average Exercise Price
ClassOfWarrantExpiredWeightedAverageExercisePrice
|
10.00 | ||
ogen |
Class Of Warrant Granted In Period Weighted Average Exercise Price
ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice
|
0 | ||
ogen |
Class Of Warrant Exercised Weighted Average Exercise Price
ClassOfWarrantExercisedWeightedAverageExercisePrice
|
1.50 | ||
ogen |
Class Of Warrant Expired
ClassOfWarrantExpired
|
5000 | shares | |
ogen |
Class Of Warrant Exercised
ClassOfWarrantExercised
|
210000 | shares | |
CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
14900000 | |
CY2013 | ogen |
Class Of Warrant Expired Weighted Average Exercise Price
ClassOfWarrantExpiredWeightedAverageExercisePrice
|
19.87 | |
CY2013 | ogen |
Class Of Warrant Granted In Period Weighted Average Exercise Price
ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice
|
0 | |
CY2013 | ogen |
Class Of Warrant Exercised Weighted Average Exercise Price
ClassOfWarrantExercisedWeightedAverageExercisePrice
|
1.50 | |
CY2013 | ogen |
Class Of Warrant Expired
ClassOfWarrantExpired
|
288888 | shares |
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
CY2013Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27515372 | shares |
CY2013 | ogen |
Class Of Warrant Granted In Period
ClassOfWarrantGrantedInPeriod
|
0 | shares |
CY2013 | ogen |
Class Of Warrant Exercised
ClassOfWarrantExercised
|
200000 | shares |
CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
13000000 | |
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.00 | |
CY2013Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.34 | |
CY2013Q3 | us-gaap |
Gross Profit
GrossProfit
|
139990 | |
CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9325424 | |
CY2013Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9325465 | |
CY2013Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
41 | |
CY2013Q3 | us-gaap |
Revenues
Revenues
|
253374 | |
CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9325424 | |
CY2013Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3611 | |
CY2013Q3 | us-gaap |
Interest Expense
InterestExpense
|
1546 | |
CY2013Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
9465455 | |
CY2013Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6907250 | |
CY2013Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2558205 | |
CY2013Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
CY2013Q3 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
113384 | |
CY2013Q3 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
2024 | |
CY2013Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1538343 | |
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.00 | |
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
CY2014Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36178944 | shares |
CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.03 | |
CY2014Q3 | us-gaap |
Gross Profit
GrossProfit
|
127299 | |
CY2014Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1029544 | |
CY2014Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1034849 | |
CY2014Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
5305 | |
CY2014Q3 | us-gaap |
Revenues
Revenues
|
201010 | |
CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1029544 | |
CY2014Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
8656 | |
CY2014Q3 | us-gaap |
Interest Expense
InterestExpense
|
1305 | |
CY2014Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
1162148 | |
CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
597034 | |
CY2014Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
565114 | |
CY2014Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
CY2014Q3 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
73711 | |
CY2014Q3 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
2046 | |
CY2014Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
34109 |